MiNK Therapeutics, Inc. 8-K

What Happened MiNK Therapeutics, Inc. (INKT) filed an 8‑K (Item 5.07) reporting the results of its Annual Meeting of Stockholders held on June 17, 2026. A total of 3,277,906 shares (65.79% of shares outstanding and eligible to vote) were present or represented by proxy, constituting a quorum. Stockholders elected Garo Armen, Barbara Ryan and John Holcomb as Class II directors for three‑year terms expiring at the 2029 Annual Meeting, and ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Meeting date and filing: Annual Meeting held June 17, 2026; Form 8‑K filed June 23, 2026 (Item 5.07).
• Shares present/representation: 3,277,906 shares, representing 65.79% of outstanding shares eligible to vote (quorum).
• Director election votes:
  • Garo Armen: For 2,363,360; Against 0; Withheld 32,898; Broker non‑votes 881,648.
  • Barbara Ryan: For 2,362,760; Against 0; Withheld 33,498; Broker non‑votes 881,648.
  • John Holcomb: For 2,381,491; Against 0; Withheld 14,767; Broker non‑votes 881,648.
• Auditor ratification (Proposal 2): For 3,249,124; Against 26,560; Abstain 2,222; Broker non‑votes 0.
• Report signed by Jennifer S. Buell, Ph.D., President and CEO.

Why It Matters The re‑election of all three Class II directors maintains the current board composition and governance continuity through 2029. Ratification of KPMG as the independent auditor establishes the firm responsible for auditing the company’s financial statements for fiscal 2026, which is a routine but important governance vote for investors monitoring audit oversight. The vote tallies and quorum percentage provide transparency on shareholder engagement and support levels.